<DOC>
	<DOC>NCT02161757</DOC>
	<brief_summary>A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist</brief_summary>
	<brief_title>A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma</brief_title>
	<detailed_description>This is a randomized, double-blind, parallel group, placebo-controlled study designed to evaluate efficacy and safety of tralokinumab administered subcutaneously in subjects with uncontrolled asthma on inhaled corticosteroid plus long-acting β2-agonist and having a history of asthma exacerbations. Approximately 1140 subjects will be randomized globally. Subjects will receive tralokinumab, or placebo, administered via subcutaneous injection at the study site, over a 52-week treatment period.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Age 12 75 2. Documented physiciandiagnosed asthma. 3. Documented treatment with ICS at a total daily dose corresponding to ≥500μg fluticasone propionate dry powder formulation equivalents) and a LABA 4. Morning preBD FEV1 value of ≥40 and &lt;80% value (&lt;90% for patients 12 to 17 years of age) of their PNV. 5. PostBD reversibility of ≥12% and ≥200 mL in FEV1 6. ACQ6 score ≥1.5 1. Pulmonary disease other than asthma 2. History of anaphylaxis following any biologic therapy 3. Hepatitis B, C or HIV 4. Pregnant or breastfeeding 5. History of cancer 6. Current tobacco smoking or a history of tobacco smoking for ≥ 10 packyears 7. Previous receipt of tralokinumab</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Reactive Airways</keyword>
	<keyword>Respiratory Tract Disease</keyword>
	<keyword>Obstructive Lung Disease</keyword>
	<keyword>Lung Diseases</keyword>
</DOC>